Udayan Chatterji
Overview
Explore the profile of Udayan Chatterji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bobardt M, Kuo J, Chatterji U, Wiedemann N, Vuagniaux G, Gallay P
PLoS One
. 2020 Jan;
15(1):e0227715.
PMID: 31978106
The immune checkpoint programmed cell death protein 1 (PD-1) plays a major role in T cell exhaustion in cancer and chronic HIV infection. The inhibitor of apoptosis protein antagonist Debio...
2.
Kuo J, Bobardt M, Chatterji U, Mayo P, Trepanier D, Foster R, et al.
J Pharmacol Exp Ther
. 2019 Aug;
371(2):231-241.
PMID: 31406003
Previous studies show that cyclophilins contribute to many pathologic processes, and cyclophilin inhibitors demonstrate therapeutic activities in many experimental models. However, no drug with cyclophilin inhibition as the primary mode...
3.
Gallay P, Ure D, Bobardt M, Chatterji U, Ou J, Trepanier D, et al.
PLoS One
. 2019 Jun;
14(6):e0217433.
PMID: 31181107
Hepatitis B virus (HBV) infection is a major health burden worldwide with 240 million chronically infected individuals. Nucleos(t)ide analogs and interferons are the current standards of care due to their...
4.
Bobardt M, Kuo J, Chatterji U, Chanda S, Little S, Wiedemann N, et al.
PLoS One
. 2019 Feb;
14(2):e0211746.
PMID: 30716099
Antiretroviral therapy (ART) suppresses HIV replication, but does not cure the infection because replication-competent virus persists within latently infected CD4+ T cells throughout years of therapy. These reservoirs contain integrated...
5.
Gallay P, Chatterji U, Kirchhoff A, Gandarilla A, Pyles R, Baum M, et al.
Open Virol J
. 2018 Mar;
12:1-13.
PMID: 29541273
Introduction: In the absence of a vaccine, there is an urgent need for the identification of effective agents that prevent HIV transmission in uninfected individuals. Non-vaccine Biomedical Prevention (nBP) methods,...
6.
de Wilde A, Zevenhoven-Dobbe J, Beugeling C, Chatterji U, de Jong D, Gallay P, et al.
Virology
. 2017 Dec;
517:148-156.
PMID: 29249267
Cyclophilin A (CypA) is an important host factor in the replication of a variety of RNA viruses. Also the replication of several nidoviruses was reported to depend on CypA, although...
7.
Gallay P, Chatterji U, Kirchhoff A, Gandarilla A, Gunawardana M, Pyles R, et al.
PLoS One
. 2017 Sep;
12(9):e0184303.
PMID: 28880948
With more than 7,000 new HIV infections daily worldwide, there is an urgent need for non-vaccine biomedical prevention (nBP) strategies that are safe, effective, and acceptable. Clinical trials have demonstrated...
8.
Chatterji U, Bobardt M, Schaffer L, Wood M, Gallay P
PLoS One
. 2016 Jul;
11(7):e0159511.
PMID: 27442520
The mechanisms of action by which cyclophilin inhibitors (CypI) interfere with the HCV life cycle remain poorly understood. We reported that CypI and NS5A inhibitors (NS5Ai), but not other classes...
9.
Gallay P, Chatterji U, Bobardt M, Long Z, Zhang S, Su Z
PLoS One
. 2016 Apr;
11(4):e0152036.
PMID: 27104614
Shortened current direct-acting antiviral (DAA) therapies while less expensive, have not provided satisfactory efficacy in naïve cirrhotics, treatment experienced non-cirrhotics or even genotype-3 (GT3)-infected patients. Since DAA regimens consist of...
10.
Veazey R, Chatterji U, Bobardt M, Russell-Lodrigue K, Li J, Wang X, et al.
Antimicrob Agents Chemother
. 2015 Nov;
60(1):693-8.
PMID: 26552985
A safe and effective vaginal microbicide could decrease human immunodeficiency virus (HIV) transmission in women. Here, we evaluated the safety and microbicidal efficacy of a short amphipathic peptide, C5A, in...